Lineage Cell Therapeutics Net Income

As of the most recent data (June 2026), LCTX shows a net income of $-32M. That compares with $-41M in the prior-year period — up 21.1% year over year. That is below the Healthcare sector average of $16B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LCTX's net income is now $-32M (was $-41M) — a 21.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Lineage Cell Therapeutics is outperforming or lagging.

The Healthcare sector average net income is about $16B. Lineage Cell Therapeutics is at $-32M, which is lower that average. That is roughly 100.2% below the sector mean. Use the comparison chart on this page to see how LCTX stacks up against individual peers as well.

Tracking LCTX's net income over time shows whether Lineage Cell Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-32M That compares with $-41M in the prior-year period — up 21.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net income page, Stockcircle has Lineage Cell Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-32M) with ownership activity and broader fundamentals.